Skip to main content
. 2022 Apr 29;11:100164. doi: 10.1016/j.jvacx.2022.100164

Table 1.

F-statistics, means and standard deviations for the three vaccination groups.

F (df1, df2) Vaccinated (n = 698) Hesitants (n = 500) No plans to get vaccinated (n = 456)
Knowledge of BioNTech 30.92***
(1, 1645)
3.46a
(0.86)
3.07b
(0.68)
2.97a,b
(0.86)
Knowledge of Sinovac 34.26***
(1, 1645)
3.40c
(0.92)
2.98d
(0.72)
2.87c,d
(0.95)
Perceived susceptibility to infection 6.82**
(1, 1645)
2.85e
(1.00)
2.67f
(0.74)
2.64e,f
(0.83)
Risks from coronavirus 2.25
(1, 1645)
48.65 (22.95) 48.51 (19.75) 50.97 (21.12)
Risks from vaccination in general 41.84***
(1, 1645)
36.22 g (25.98) 38.38 h (19.73) 49.56 g,h (22.43)
Benefits of BioNTech 92.30***
(1, 1645)
3.70i,j
(0.69)
3.47j,k
(0.53)
3.11i,k
(0.76)
Benefits of Sinovac 156.36***
(1, 1645)
3.25 l,m
(0.94)
2.71 m,n
(0.76)
2.16 l,n
(0.86)
Risks from BioNTech 6.83**
(1, 1645)
3.23o,p
(0.77)
3.33o
(0.57)
3.37p
(0.67)
Risks from Sinovac 26.88***
(1, 1645)
3.12q,r
(0.84)
3.25q,s
(0.67)
3.50r,s
(0.91)

Notes. ** p <.01. *** p <.001. a–s Mean is statistically different from the mean of the relevant comparison group indicated by the same letter at a 0.05 significance level. Standard deviations are reported in brackets. All comparisons controlled for gender, age, education, income, party identification and health status.